NASDAQ:BBIO - Nasdaq - US10806X1028 - Common Stock - Currency: USD
The phase I study evaluates BAYRY's investigational GIRK4 inhibitor, BAY 3670549, for the treatment of patients with atrial fibrillation.
The Home Depot, Inc. (NYSE:HD) is capitalizing on customers tackling smaller projects. That’s one of the company’s strategies as it navigates a challenging macroenvironment worsened by the US-China tariff war. That was evident after the home improvement retailer delivered solid first-quarter results on Tuesday. Net sales were up 9% year over year to $39.86 billion […]
On May 20, Schrödinger, Inc. (NASDAQ:SDGR) announced the departure of Chief Financial Officer Geoffrey Porges, MBBS., who is stepping down to pursue other opportunities. Richie Jain, previously Senior Vice President of Strategic Finance and Head of Corporate and Business Development, will succeed him. Dr. Porges will continue as an advisor until June 6, 2025, to […]
On May 19, Workday Inc. (NASDAQ:WDAY) unveiled Illuminate AI Agents, a new generation of AI-powered tools aimed at accelerating hiring, enhancing frontline worker experiences, and streamlining financial processes. Designed to boost productivity, these agents integrate Workday’s responsible AI foundation and extensive HR and finance expertise. “The key to unlocking real business value with AI is […]
On May 19, BMO Capital Markets reaffirmed its “Market Perform” rating and $64.00 price target for Novo Nordisk A/S (NYSE:NVO) following the announcement of a CEO transition. Analysts view the leadership change as a response to competitive pressures and shareholder demands, but warn that without a strategic shift, challenges may persist. On May 16, Novo […]
On May 19, CrowdStrike Holdings, Inc. (NASDAQ:CRWD) announced its integration into the NVIDIA Enterprise AI Factory validated design, enabling enterprises to protect AI infrastructure, systems, and models as they scale AI adoption. With NVIDIA Blackwell infrastructure, this validated design provides a full-stack AI ecosystem—covering data ingestion, model training, deployment, and runtime use—to help businesses harness […]
Here is how Alignment Healthcare (ALHC) and BridgeBio Pharma (BBIO) have performed compared to their sector so far this year.
Mentions: ALHC
- In a post-hoc analysis of ATTRibute-CM, acoramidis reduced the annual frequency of CVH due to AF/AFL by 43% compared to placebo and reduced the incidence...
- For each 5-mg/dL increase in serum TTR level within 28 days of starting treatment, the relative risk reduction of mortality was up to 31.6% through Month...
PALO ALTO, Calif., May 14, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical...
The regulator aims to reduce costs and improve access to insurance, while ensuring “appropriate” protection levels are maintained.
We recently published an article titled Massive Sell-Offs Just Hit These 10 Stocks Today. In this article, we are going to take a look at where BridgeBio Pharma, Inc. (NASDAQ:BBIO) stands against the other stocks. Wall Street’s main indices finished mixed on Tuesday, as investors digested the country’s latest inflation figures, which came out lower than […]
American Eagle Outfitters (AEO) shares fell early Wednesday as the clothing retailer said it expects
The average of price targets set by Wall Street analysts indicates a potential upside of 63.9% in BridgeBio Pharma (BBIO). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
- ATTRibute-CM, BridgeBio’s Phase 3 clinical trial of acoramidis in patients with ATTR-CM, achieved statistical significance in reducing the risk of ACM or...
PALO ALTO, Calif., May 12, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical...
PALO ALTO, Calif., May 07, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical...
Alnylam analysts highlight Amvuttra's strong launch positioning and limited tariff risk, with bullish ratings maintained despite early launch volatility.
Mentions: ALNY
We recently published a list of 10 Best Cybersecurity Stocks to Invest in Under $20. In this article, we are going to take a look at where Identiv, Inc. (NASDAQ:INVE) stands against other best cybersecurity stocks to invest in under $20. The cybersecurity sector is at a tipping point, driven by growing cyber threats, breakthrough […]
We recently published a list of 10 Best Cybersecurity Stocks to Invest in Under $20. In this article, we are going to take a look at where Telos Corporation (NASDAQ:TLS) stands against other best cybersecurity stocks to invest in under $20. The cybersecurity sector is at a tipping point, driven by growing cyber threats, breakthrough […]
Learn ways to manage your semi-truck loan and what to do if you can’t make payments.
We recently published an article titled Excellent Earnings Propelled Prices of These 10 Firms. In this article, we are going to take a look at where BridgeBio Pharma, Inc. (NASDAQ:BBIO) stands against the other stocks that soared on Wednesday. The stock market finished Wednesday’s trading on a lackluster note, with the three major indices finishing mixed, as […]
We recently published an article titled Excellent Earnings Propelled Prices of These 10 Firms. In this article, we are going to take a look at where Mondelez International, Inc. (NASDAQ:MDLZ) stands against the other stocks that soared on Wednesday. The stock market finished Wednesday’s trading on a lackluster note, with the three major indices finishing mixed, as […]
National Bank initiated coverage of McEwen Mining (MUX) with an Outperform rating and C$20 price target The company’s Los Azules copper mega-project shows mega-rerate potential, though the stock’s The valuation disparity is largely explained by the Los Azules project stage, time until start of development, financing and construction de-risking, and the constraints faced by a junior to clear these value impediments, the analyst tells investors in a research note. Published first on TheFly – the u
BridgeBio Pharma (BBIO) delivered earnings and revenue surprises of 12% and 86.76%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Mentions: ASMB
Cantor Fitzgerald analyst Steve Seedhouse assumed coverage of ProQR Therapeutics (PRQR) with an Overweight rating and $8 price target ProQR is a leader in RNA editing and the initial biomarker data for its first program targeting bile acid transporter in Q4 will be an “important catalyst,” the analyst tells investors in a research note. Cantor views the company as a “pure play” on RNA editing. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. T
The company sells a rival to Pfizer' heart treatment, Vyndaqel. Sales smashed expectations in its first quarter on the market.
- $36.7 million in first full quarter of U.S. Attruby™ net product revenue and as of April 25, 2025, 2,072 unique patient prescriptions written by 756...
We recently published a list of Billionaire Andreas Halvorsen’s 10 Stock Picks With Huge Upside Potential. In this article, we are going to take a look at where BridgeBio Pharma, Inc. (NASDAQ:BBIO) stands against other billionaire Andreas Halvorsen’s stock picks with huge upside potential. Ole Andreas Halvorsen is one of the prominent names among former […]
We recently published a list of Billionaire Andreas Halvorsen’s 10 Stock Picks With Huge Upside Potential. In this article, we are going to take a look at where BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) stands against other billionaire Andreas Halvorsen’s stock picks with huge upside potential. Ole Andreas Halvorsen is one of the prominent names among former […]
Paying for college is a challenge for many students, but student loans can help.